{
  "pmid": "30916798",
  "uid": "30916798",
  "title": "Reversal of direct oral anticoagulants: Guidance from the Anticoagulation Forum.",
  "abstract": "Two specific reversal agents for direct oral anticoagulants (DOACs) have been approved in the United States: idarucizumab for dabigatran reversal and andexanet alfa for apixaban and rivaroxaban reversal. Non-specific prohemostatic agents such as prothrombin complex concentrate (PCC) and activated PCC have also been used for DOAC reversal. The goal of this document is to provide comprehensive guidance from the Anticoagulation Forum, a North American organization of anticoagulation providers, regarding use of DOAC reversal agents. We discuss indications for reversal, provide guidance on how the individual reversal agents should be administered, and offer suggestions for stewardship at the health system level.",
  "authors": [
    {
      "last_name": "Cuker",
      "fore_name": "Adam",
      "initials": "A",
      "name": "Adam Cuker",
      "affiliations": [
        "Department of Medicine and Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania."
      ],
      "orcid": "0000-0002-3595-5697"
    },
    {
      "last_name": "Burnett",
      "fore_name": "Allison",
      "initials": "A",
      "name": "Allison Burnett",
      "affiliations": [
        "Department of Pharmacy Practice and Administrative Sciences, University of New Mexico Health Sciences Center, Albuquerque, New Mexico."
      ]
    },
    {
      "last_name": "Triller",
      "fore_name": "Darren",
      "initials": "D",
      "name": "Darren Triller",
      "affiliations": [
        "WellScriptEd Consulting, Inc., Clifton Park, New York."
      ]
    },
    {
      "last_name": "Crowther",
      "fore_name": "Mark",
      "initials": "M",
      "name": "Mark Crowther",
      "affiliations": [
        "Department of Medicine, McMaster University, Hamilton, Ontario, Canada."
      ]
    },
    {
      "last_name": "Ansell",
      "fore_name": "Jack",
      "initials": "J",
      "name": "Jack Ansell",
      "affiliations": [
        "Department of Medicine, Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York."
      ]
    },
    {
      "last_name": "Van Cott",
      "fore_name": "Elizabeth M",
      "initials": "EM",
      "name": "Elizabeth M Van Cott",
      "affiliations": [
        "Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts."
      ]
    },
    {
      "last_name": "Wirth",
      "fore_name": "Diane",
      "initials": "D",
      "name": "Diane Wirth",
      "affiliations": [
        "Department of Cardiology, Grady Memorial Hospital, Atlanta, Georgia."
      ]
    },
    {
      "last_name": "Kaatz",
      "fore_name": "Scott",
      "initials": "S",
      "name": "Scott Kaatz",
      "affiliations": [
        "Division of Hospital Medicine, Henry Ford Hospital, Detroit, Michigan."
      ]
    }
  ],
  "journal": {
    "title": "American journal of hematology",
    "iso_abbreviation": "Am J Hematol",
    "issn": "1096-8652",
    "issn_type": "Electronic",
    "volume": "94",
    "issue": "6",
    "pub_year": "2019",
    "pub_month": "Jun"
  },
  "start_page": "697",
  "end_page": "709",
  "pages": "697-709",
  "language": "eng",
  "publication_types": [
    "Journal Article",
    "Research Support, Non-U.S. Gov't",
    "Systematic Review"
  ],
  "keywords": [
    "Antibodies, Monoclonal, Humanized",
    "Anticoagulants",
    "Factor Xa",
    "Humans",
    "Practice Guidelines as Topic",
    "Recombinant Proteins"
  ],
  "article_ids": {
    "pubmed": "30916798",
    "doi": "10.1002/ajh.25475"
  },
  "doi": "10.1002/ajh.25475",
  "dates": {
    "completed": "2020-01-28",
    "revised": "2020-01-28"
  },
  "chemicals": [
    "Antibodies, Monoclonal, Humanized",
    "Anticoagulants",
    "PRT064445",
    "Recombinant Proteins",
    "idarucizumab",
    "Factor Xa"
  ],
  "grants": [
    {
      "agency": "Janssen Pharmaceuticals",
      "country": "International"
    },
    {
      "agency": "Asahi Kasei Pharma Corporation",
      "country": "International"
    },
    {
      "agency": "Diagnostica Stago",
      "country": "International"
    },
    {
      "agency": "Servier Canada",
      "country": "International"
    },
    {
      "agency": "CSL Behring",
      "country": "International"
    },
    {
      "agency": "BMS Canada",
      "country": "International"
    },
    {
      "agency": "Octapharma",
      "country": "International"
    },
    {
      "agency": "Shionogi",
      "country": "International"
    },
    {
      "agency": "Leo Pharma Research Foundation",
      "country": "International"
    },
    {
      "agency": "Heart and Stroke Foundation",
      "country": "International"
    },
    {
      "agency": "Syntimmune",
      "country": "International"
    },
    {
      "agency": "Spark Therapeutics",
      "country": "International"
    },
    {
      "agency": "Shire",
      "country": "International"
    },
    {
      "agency": "Pfizer",
      "country": "International"
    },
    {
      "agency": "Novo Nordisk",
      "country": "International"
    },
    {
      "agency": "Bioverativ",
      "country": "International"
    },
    {
      "agency": "Bayer",
      "country": "International"
    },
    {
      "agency": "Alexion",
      "country": "International"
    }
  ],
  "search_metadata": {
    "search_type": "current_affiliation",
    "retrieved_date": "2025-07-30T14:16:41.695177",
    "pmid": "30916798"
  }
}